Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

CYT - Cyteir Therapeutics, Inc.

IEX Last Trade
2.725
0.005   0.183%

Share volume: 350,916
Last Updated: Tue 08 Aug 2023 09:54:55 PM CEST
Pharmaceutical Preparation Manufacturing : 2.72%

PREVIOUS CLOSE
CHG
CHG%
$2.72
0.01
0.18%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
57%
Profitability 68%
Dept financing 0%
Liquidity 0%
Performance 75%
Performance
5 Days
-0.37%
1 Month
-1.09%
3 Months
23.08%
6 Months
65.85%
1 Year
9.24%
2 Year
-86.07%
Key data
Stock price
$2.72
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$1.13 - $2.81
52 WEEK CHANGE
$0.05
MARKET CAP 
96.832 M
YIELD 
N/A
SHARES OUTSTANDING 
35.600 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
1.01
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$336,715
AVERAGE 30 VOLUME 
$214,374
Company detail
CEO: Markus F. Renschler
Region: US
Website: cyteir.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851 is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.

Recent news